Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 9Endocrine 9Plasma cell 2Other hematologic neoplasm 2Gastrointestinal 2CNS 2Thoracic 1Sarcoma 1Myeloid 1Lymphoid 1Gynecologic 1

Conditions

Sarcoma 2Neoplasm Metastasis 2Gastrointestinal Stromal Tumors 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Osteosarcoma 1Nonseminomatous germ cell tumor 1Neoplasms 1Multiple Myeloma 1Leukemia, Hairy Cell 1Glioma 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Advanced Solid Tumors 1

Interventions

trametinib 1tislelizumab 1surufatinib 1fludarabine 1dabrafenib 1aldesleukin 1Tamoxifen 1Radiotherapy 1Nivolumab 1Ipilimumab 1Doxorubicin 1Cyclophosphamide 1Cisplatin 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × trametinib × Sarcoma × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡